KR20220005066A - 항생제 칸나비노이드-테르펜 제형 - Google Patents

항생제 칸나비노이드-테르펜 제형 Download PDF

Info

Publication number
KR20220005066A
KR20220005066A KR1020217039392A KR20217039392A KR20220005066A KR 20220005066 A KR20220005066 A KR 20220005066A KR 1020217039392 A KR1020217039392 A KR 1020217039392A KR 20217039392 A KR20217039392 A KR 20217039392A KR 20220005066 A KR20220005066 A KR 20220005066A
Authority
KR
South Korea
Prior art keywords
infection
cannabinoid
formulation
daptomycin
enterococcus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217039392A
Other languages
English (en)
Korean (ko)
Inventor
찰스 제이 톰슨
마크 씨 프리지마
다나 엠 램버트
마니샤 도산즈
Original Assignee
더 유니버시티 오브 브리티쉬 콜롬비아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유니버시티 오브 브리티쉬 콜롬비아 filed Critical 더 유니버시티 오브 브리티쉬 콜롬비아
Publication of KR20220005066A publication Critical patent/KR20220005066A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217039392A 2019-05-06 2020-05-06 항생제 칸나비노이드-테르펜 제형 Withdrawn KR20220005066A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843687P 2019-05-06 2019-05-06
US62/843,687 2019-05-06
PCT/CA2020/050613 WO2020223811A1 (en) 2019-05-06 2020-05-06 Antibiotic cannabinoid-terpene formulations

Publications (1)

Publication Number Publication Date
KR20220005066A true KR20220005066A (ko) 2022-01-12

Family

ID=73050953

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217039392A Withdrawn KR20220005066A (ko) 2019-05-06 2020-05-06 항생제 칸나비노이드-테르펜 제형

Country Status (11)

Country Link
US (3) US20220218654A1 (https=)
EP (1) EP3965794A4 (https=)
JP (1) JP2022532116A (https=)
KR (1) KR20220005066A (https=)
CN (1) CN113710263A (https=)
AU (1) AU2020270175A1 (https=)
CA (1) CA3138811A1 (https=)
IL (1) IL287729A (https=)
MX (1) MX2021013656A (https=)
SG (1) SG11202110779SA (https=)
WO (1) WO2020223811A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102524364B1 (ko) * 2022-10-24 2023-04-24 전북대학교산학협력단 칸나비디올 및 타우린을 포함하는 치주염 예방 또는 치료용 조성물

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013656A (es) * 2019-05-06 2022-01-06 Univ British Columbia Formulaciones antibioticas de cannabinoides-terpenos.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630507B1 (en) 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
US7323576B2 (en) 2004-10-01 2008-01-29 Alphora Research Inc. Synthetic route to dronabinol
WO2012012498A2 (en) 2010-07-20 2012-01-26 Pulmatrix, Inc. Use of trp channel agonists to treat infections
CN107405314A (zh) * 2015-02-27 2017-11-28 埃布公司 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物
AU2016225026A1 (en) * 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
EP3380096A4 (en) * 2015-11-24 2019-10-23 Constance Therapeutics, Inc. CANNABIS OIL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
WO2018011813A1 (en) 2016-07-14 2018-01-18 Therapix Biosciences Ltd. Compositions and methods of potentiating antimicrobials
CA3067542A1 (en) * 2017-06-19 2018-12-27 Syddansk Universitet Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections
WO2019198056A1 (en) * 2018-04-14 2019-10-17 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition for treating conditions and/ or symptoms associated with a stressful event
WO2020000024A1 (en) * 2018-06-28 2020-01-02 Botanix Pharmaceuticals Ltd Antibacterial treatment using cannabinoid combinations
CA3111979A1 (en) * 2018-09-05 2020-03-12 Nemus Bioscience, Inc. Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains
MX2021013656A (es) * 2019-05-06 2022-01-06 Univ British Columbia Formulaciones antibioticas de cannabinoides-terpenos.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102524364B1 (ko) * 2022-10-24 2023-04-24 전북대학교산학협력단 칸나비디올 및 타우린을 포함하는 치주염 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
SG11202110779SA (en) 2021-10-28
JP2022532116A (ja) 2022-07-13
MX2021013656A (es) 2022-01-06
IL287729A (en) 2021-12-01
EP3965794A4 (en) 2023-01-18
CA3138811A1 (en) 2020-11-12
CN113710263A (zh) 2021-11-26
US20230355573A1 (en) 2023-11-09
US11744819B2 (en) 2023-09-05
AU2020270175A1 (en) 2021-12-02
WO2020223811A1 (en) 2020-11-12
US20220233494A1 (en) 2022-07-28
US20220218654A1 (en) 2022-07-14
EP3965794A1 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
US20230355573A1 (en) Antibiotic cannabinoid-terpene formulations
AU2009285564B2 (en) Methods of treatment using single doses of oritavancin
EP2648703A1 (en) Pharmaceutical composition comprising trans-cinnamaldehyde and its use in the treatment of infections
US20230248745A1 (en) Silver enhanced cannabinoid antibiotics
US10668043B2 (en) Potentiated antimicrobial agents
HK40064842A (en) Antibiotic cannabinoid-terpene formulations
US20160206687A1 (en) Methods for treating bacterial infections using oritavancin and polymyxins
WO2025213249A1 (en) Silver enhanced cannabinoid antibiotics
KR102670265B1 (ko) 테트라메틸부틸하이드로퀴논을 유효성분으로 포함하는 황색포도상구균 바이오필름 형성 억제용 조성물
US10765659B2 (en) Potentiated tulathromycin
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000